<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>bullous pemphigoid &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/bullous-pemphigoid/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 12 Oct 2026 14:26:08 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>bullous pemphigoid &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Insurance Red Tape Keeps Blistering Disease Patients From Lifesaving Biologics</title>
		<link>https://bioengineer.org/insurance-red-tape-keeps-blistering-disease-patients-from-lifesaving-biologics/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Mon, 12 Oct 2026 14:26:08 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[autoimmune blistering diseases]]></category>
		<category><![CDATA[biologic therapy]]></category>
		<category><![CDATA[bullous pemphigoid]]></category>
		<category><![CDATA[Dermatology]]></category>
		<category><![CDATA[health insurance]]></category>
		<category><![CDATA[healthcare access]]></category>
		<category><![CDATA[patient survey]]></category>
		<category><![CDATA[pemphigus vulgaris]]></category>
		<category><![CDATA[prior authorization]]></category>
		<category><![CDATA[rare disease]]></category>
		<category><![CDATA[rituximab]]></category>
		<category><![CDATA[step therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=415858</guid>

					<description><![CDATA[A new survey of United States patients with autoimmune blistering diseases documents how insurance requirements such as prior authorization and step therapy delay access to biologic therapies that clinical trials show work best when started early.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">415858</post-id>	</item>
	</channel>
</rss>
